{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:57:49Z","timestamp":1792929469453,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203930\/B\/16\/Z"],"award-info":[{"award-number":["203930\/B\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001593","name":"Irish Cancer Society","doi-asserted-by":"publisher","award":["14\/ICS\/B3042"],"award-info":[{"award-number":["14\/ICS\/B3042"]}],"id":[{"id":"10.13039\/501100001593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jcyt.2022.07.008","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T07:53:38Z","timestamp":1661759618000},"page":"1087-1094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Concurrent transposon engineering and CRISPR\/Cas9 genome editing of primary CLL-1 chimeric antigen receptor\u2013natural killer cells"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7062-2644","authenticated-orcid":false,"given":"Mark","family":"Gurney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8622-9484","authenticated-orcid":false,"given":"Eimear","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Brophy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0631-103X","authenticated-orcid":false,"given":"Janusz","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Hermanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Szegezdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"O'Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2022.07.008_bib0001","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0002","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-021-02406-6","article-title":"Nonviral genome engineering of natural killer cells","volume":"12","author":"Robbins","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0004","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/leu.2016.180","article-title":"Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors","volume":"31","author":"Monjezi","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.gde.2018.06.003","article-title":"Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system","volume":"52","author":"Hudecek","year":"2018","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0006","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2019-129562","article-title":"Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed\/Refractory (r\/r) Multiple Myeloma (MM) (PRIME)","volume":"134","author":"Costello","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0007","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1172\/JCI138473","article-title":"Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities","volume":"130","author":"Magnani","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0008","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma","volume":"28","author":"Prommersberger","year":"2021","journal-title":"Gene Ther"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0009","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-generation cell therapies: The emerging role of CAR-NK cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0010","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0011","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1016\/j.bbmt.2018.12.317","article-title":"First-in-Human Phase I Study of Nicotinamide-Expanded Related Donor Natural Killer Cells for the Treatment of Relapsed\/Refractory Non-Hodgkin Lymphoma and Multiple Myeloma","volume":"25","author":"Bachanova","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0012","first-page":"1","article-title":"Decrease post-transplant relapse using donor-derived expanded NK-cells","volume":"2021","author":"Ciurea","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0013","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-141606","article-title":"Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed\/Refractory B-Cell Lymphoma","volume":"136","author":"Bachanova","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0014","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0016","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.omtm.2021.01.008","article-title":"Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion","volume":"20","author":"Allan","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0017","article-title":"Preprint: Non-Viral Engineering of CAR-NK and CAR-T cells using the Tc Buster Transposon SystemTM","author":"Pomeroy","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0018","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.omtm.2021.10.014","article-title":"piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells","volume":"23","author":"Du","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0019","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3389\/fimmu.2022.802906","article-title":"Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing","volume":"13","author":"Gurney","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0020","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ni.3470","article-title":"CIS is a potent checkpoint in NK cell-mediated tumor immunity","volume":"17","author":"Delconte","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0021","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0022","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0023","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abe5137","article-title":"CISH attenuates homeostatic cytokine signaling to promote lung-specific macrophage programming and function","volume":"14","author":"Shoger","year":"2021","journal-title":"Sci Signal"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0024","doi-asserted-by":"crossref","first-page":"30266","DOI":"10.1074\/jbc.274.42.30266","article-title":"CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling","volume":"274","author":"Aman","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0025","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1084\/jem.20150304","article-title":"Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance","volume":"212","author":"Palmer","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004244","article-title":"Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity","volume":"10","author":"Bernard","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0027","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"van Rhenen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0028","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0029","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0030","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/14653240902807034","article-title":"Clinical Grade Ex Vivo-Expanded Human Natural Killer Cells Upregulate Activating Receptors and Death Receptor Ligands and Have Enhanced Cytolytic Activity against Tumor Cells","volume":"11","author":"Berg","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0031","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1219007","article-title":"Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma","volume":"5","author":"Granzin","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0032","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1","volume":"25","author":"Tashiro","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0033","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/bloodadvances.2018020107","article-title":"CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia","volume":"2","author":"Jiang","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0034","doi-asserted-by":"crossref","first-page":"6454","DOI":"10.1016\/j.vaccine.2009.06.017","article-title":"Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system","volume":"27","author":"Luke","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/crispr.2021.0113","article-title":"Inference of CRISPR Edits from Sanger Trace Data","volume":"5","author":"Conant","year":"2022","journal-title":"CRISPR J"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-27853-w","article-title":"A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers","volume":"13","author":"Wong","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0037","doi-asserted-by":"crossref","first-page":"e42666","DOI":"10.1371\/journal.pone.0042666","article-title":"Comparative Analysis of the Recently Discovered hAT Transposon TcBuster in Human Cells","volume":"7","author":"Woodard","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0038","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1182\/blood-2021-153999","article-title":"Non-Viral Sleeping Beauty Transposon Engineered CD19-CAR-NK Cells Show a Safe Genomic Integration Profile and High Antileukemic Efficiency","volume":"138","author":"Bexte","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0039","series-title":"Doctoral Thesis: Highly Efficient Activation and Expansion of Natural Killer Cells for Clinical use in Cancer Immunotherapy","author":"Granzin","year":"2016"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0040","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/cancers13040872","article-title":"RNA-Seq Analysis Reveals CCR5 as a Key Target for CRISPR Gene Editing to Regulate In Vivo NK Cell Trafficking","volume":"13","author":"Levy","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0041","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0042","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0043","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0044","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2021-148649","article-title":"Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies","volume":"138","author":"Choi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0045","article-title":"CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide","volume":"105","author":"Gurney","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0046","article-title":"CISH targeting in NK cells activates natural cytotoxicity receptor signaling and reduce cell exhaustion to unsilence primary anti-tumor response","author":"Bernard","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0047","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","article-title":"Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent","volume":"21","author":"Gomes-Silva","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0048","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0050","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0051","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3389\/fimmu.2019.02357","article-title":"Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells","volume":"10","author":"Carlsten","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0052","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/bloodadvances.2017015230","article-title":"Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy","volume":"2","author":"Mastaglio","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0053","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1046\/j.1365-2141.2002.03495.x","article-title":"Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells","volume":"117","author":"Lowdell","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0054","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0055","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood-2006-07-038687","article-title":"Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value","volume":"110","author":"Ruggeri","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0056","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0057","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0058","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3324\/haematol.2018.208751","article-title":"Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: How close to reality?","volume":"104","author":"Cummins","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0059","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1016\/j.bbmt.2016.12.413","article-title":"Targeting CLEC12A with Chimeric Antigen Receptor T Cells Can Overcome the Chemotherapy Refractoriness of Leukemia Stem Cells","volume":"23","author":"Kenderian","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0726-5","article-title":"Targeting CLL-1 for acute myeloid leukemia therapy","volume":"12","author":"Ma","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0061","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-017-0553-5","article-title":"CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0062","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","article-title":"Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed\/refractory acute myeloid leukemia","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0063","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.561553","article-title":"Umbilical Cord Blood and iPSC-Derived Natural Killer Cells Demonstrate Key Differences in Cytotoxic Activity and KIR Profiles","volume":"11","author":"Goldenson","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2022.07.008_bib0064","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324922007393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324922007393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:48:33Z","timestamp":1761443313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324922007393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1465324922007393"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2022.07.008","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concurrent transposon engineering and CRISPR\/Cas9 genome editing of primary CLL-1 chimeric antigen receptor\u2013natural killer cells","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2022.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}